Antares Pharma Upgraded by Zacks to “Neutral” (ATRS) - InvestingChannel

Antares Pharma Upgraded by Zacks to “Neutral” (ATRS)

Antares Pharma traded up 0.72% on Tuesday, hitting $4.22. Antares Pharma has a 52-week low of $2.16 and a 52-week high of $5.58. The stock?s 50-day moving average is currently $3.91. The company?s market cap is $528.1 million.

Antares Pharma last posted its quarterly earnings results on Wednesday, November 7th. The company reported ($0.03) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.03). The company had revenue of $5.68 million for the quarter, compared to the consensus estimate of $5.62 million. During the same quarter in 2012, the company posted ($0.01) earnings per share. The company?s quarterly revenue was up 45.3% on a year-over-year basis. Analysts expect that Antares Pharma will post $-0.08 EPS for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Jefferies Group initiated coverage on shares of Antares Pharma in a research note to investors on Wednesday, December 19th. They set a ?buy? rating and a $5.00 price target on the stock. Analysts at Guggenheim initiated coverage on shares of Antares Pharma in a research note to investors on Monday, November 26th. They set a ?buy? rating and a $6.00 price target on the stock. Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. To view Zacks? full report, visit www.zacks.com

Stay on top of analysts’ coverage with American Banking & Market News’ that provides a concise list of analysts’ upgrades, analysts’ downgrades and analysts’ price target changes for each day..